title: Taurine infused intrastriatally elevates, but intranigrally decreases striatal extracellular dopamine concentration in anaesthetised rats.
abstract: In the present study we infused taurine (50, 150 or 450 mM, 2 microliters/min for 4h) into the dorsal striatum or into the substantia nigra via microdialysis probe and estimated the extracellular concentrations of dopamine and its metabolites, 3,4-dihydroxyphenylacetic acid (DOPAC) and homovanillic acid (HVA), in the dorsal striatum of anaesthetised rats. Intrastriatal infusion of taurine elevated striatal dopamine at all concentrations studied. At the 450 mM concentration taurine elevated the extracellular dopamine 10-fold, but only in the first 30 min sample after starting the taurine infusion. At 50 and 150 mM taurine elevated dopamine throughout the 4h infusion maximally up to 3-4-fold the control level. Extracellular DOPAC was increased by 150 and 450 mM taurine (up to about 150-160% of the control level), whereas at all three concentrations taurine decreased HVA to about 85% of the control; however, the decrease caused by 450 mM taurine was short-lasting. At all three concentrations taurine infused into the substantia nigra decreased the extracellular dopamine in the ipsilateral striatum to about 40-50% of the control, and increased extracellular DOPAC and HVA maximally to about 150% and 170% of the control, respectively. These results show that the effects of taurine on the concentrations of extracellular dopamine and its metabolites depend on its administration site on nigrostriatal dopaminergic neurons. It elevates the extracellular dopamine when given into the striatum, but when given into the cell body region of the nigrostriatal dopaminergic pathway it decreases the extracellular dopamine in the ipsilateral striatum.
authors.affiliation: Department of Pharmacy, University of Helsinki, Finland.
authors.forename: M
authors.initials: M
authors.lastname: Ruotsalainen
authors.forename: M
authors.initials: M
authors.lastname: Heikkilä
authors.forename: P
authors.initials: P
authors.lastname: Lillsunde
authors.forename: T
authors.initials: T
authors.lastname: Seppälä
authors.forename: L
authors.initials: L
authors.lastname: Ahtee
mesh_terms: D015102:3,4-Dihydroxyphenylacetic Acid / Q000378:metabolism*; D000704:Analysis of Variance; D000777:Anesthetics; D000818:Animals; D003342:Corpus Striatum / Q000166:cytology / Q000187:drug effects*; D004298:Dopamine / Q000378:metabolism*; D006719:Homovanillic Acid / Q000378:metabolism*; D007263:Infusions, Parenteral; D008297:Male; D017551:Microdialysis; D009474:Neurons / Q000187:drug effects; D051381:Rats; D017208:Rats, Wistar; D013378:Substantia Nigra / Q000166:cytology / Q000187:drug effects*; D013654:Taurine / Q000494:pharmacology*
chemical_list: D000777:Anesthetics; D015102:3,4-Dihydroxyphenylacetic Acid; D013654:Taurine; D004298:Dopamine; D006719:Homovanillic Acid